Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
NCT ID: NCT01443338
Last Updated: 2011-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
720 participants
INTERVENTIONAL
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Triptergium Wilfordii
a kind of traditional chinese medicine
Triptergium Wilfordii
Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
Acitretin
Acitretin
Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triptergium Wilfordii
Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
Acitretin
Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a diagnosis of psoriasis vulgaris,PASI score of 7 or greater.
* Capable of giving informed consent and the consent must be obtained prior to any study related procedures.
Exclusion Criteria
* Have any active dermatoses which may affect disease assessment of psoriasis.
* Have used any investigational drug,any biologic or any systemic immunosuppressants within the previous 1 month..
* Have used topical medications/treatments that could affect psoriasis or PASI evaluation (eg, corticosteroids, tar, phototherapy et al.) within 2 weeks.
* Have any acute or chronic or recurrent infectious disease,which was difficult to control.
* Have the history of HBV or HCV infection,or HIV antibody test positive.
* AST, ALT or blood fat levels must be within 1.5 times the ULN range for the laboratory conducting the test.
* Are pregnant, nursing, or planning pregnancy in the coming two years(both men and women) while enrolled in the study.
* Have any severe systemic disease or have a history of malignancy.
* Have shown a previous hypersensitivity to Triptergium wilfordii or Acitretin.
* Have any other condition not suitable to join in trial,which are judged by investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, China
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Min Zheng
Head of dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lunfei Liu, Md
Role: primary
Jisu Chen, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHINA201002016-2
Identifier Type: -
Identifier Source: org_study_id